据路透社2月13日消息,IQVIA数据显示,丹麦制药公司诺和诺德(NVO.US)的明星减肥药Wegovy在上市第五周的处方量达到了38,220份。Wegovy是诺和诺德公司开发的一种用于治疗肥胖症的药物。自上市以来,该药物在美国市场的处方量持续增长,显示出其市场需求强劲。随着越来越多的医生和患者了解和认可Wegovy的疗效,预计其处方量还将进一步上升。
Source Link据路透社2月13日消息,IQVIA数据显示,丹麦制药公司诺和诺德(NVO.US)的明星减肥药Wegovy在上市第五周的处方量达到了38,220份。Wegovy是诺和诺德公司开发的一种用于治疗肥胖症的药物。自上市以来,该药物在美国市场的处方量持续增长,显示出其市场需求强劲。随着越来越多的医生和患者了解和认可Wegovy的疗效,预计其处方量还将进一步上升。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.